Dong-A on bumpy road over Stillen

Published: 2008-12-02 06:59:00

Updated: 2008-12-02 06:59:00

Dong-A Pharm is likely to face a bumpy road next year as many pharmaceutical manufacturers will rush to introduce the first version of Stillen capsule, one of Dong-A’s flagship products for treatment of gastritis, as the re-examination period of this medicine expired on June 11.

Industry watch...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK